Press Release

28 August 2024

Infographic | HitGen FY2024H1 Report

Infographic | HitGen FY2024H1 Report
22 August 2024

Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program

CHENGDU, China, August 22, 2024 – Bridge Biotherapeutics ("Bridge", KQ288330), a clinical-stage biotech company, announced that it has entered into a joint research agreement with HitGen Inc. ("HitGen", SSE: 688222.SH), a Chinese drug discovery platform company. This collaboration builds on successful initial hit finding and identification work from HitGen’s DNA-encoded library (DEL), aiming to further develop the novel hits as promising drug candidates for cancer.
24 April 2024

Infographic | HitGen FY2023&2024Q1 Report

Infographic | HitGen FY2023&2024Q1 Report
08 April 2024

Vernalis announces a drug discovery collaboration with C4X Discovery in inflammatory disease

Vernalis (R&D) Limited (“Vernalis”), a wholly owned subsidiary of HitGen Inc., and C4X Discovery (“C4XD”) are pleased to announce a collaboration to identify modulators of an undisclosed high-value target involved in inflammatory disease.
26 March 2024

HitGen Partners with LabCentral / BioLabs / MBC BioLabs to Accelerate Biotechnology Discovery

[San Francisco, CA – March 25, 2024] – LabCentral, a launchpad for high-potential life science and biotech start-ups, BioLabs, an international membership-based network of shared lab and office facilities, and MBC BioLabs, premier providers of co-working laboratory space, announced a partnership with HitGen, a global leader in the design, synthesis, and screening of DNA-encoded chemical libraries (DELs).
21 February 2024

Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology

Hox Therapeutics Ltd (“Hox”) a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors against an undisclosed oncology target.
13 November 2023

Get ready for the end-of-year sale! Discover the future of drug discovery with OpenDEL™ and save 20% off!
27 October 2023

Infographic | HitGen FY2023 Q3 Report
19 October 2023

Venture forces invest millions in new type of treatment for particularly aggressive form of cancer

A syndicate consisting of the Lundbeck Foundation BioCapital, EIR Ventures, EIFO and UCPH Ventures has just made an investment in the Danish biotech company Dania Therapeutics (Dania Tx).
28 September 2023

SGC and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, September 28, 2023 – Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a partnership with The Structural Genomics Consortium ("SGC"), a public-private partnership that supports the discovery of new medicines through open-access research. HitGen will utilize its DNA-encoded library (DEL) technology platform, specifically OpenDEL™, to screen under-represented targets chosen by SGC.

News

Press Release

Thanks for reading!